Video

Dr. Ari M. Melnick on Biomarkers in Lymphoma

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, comments on biomarkers in lymphoma.

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, comments on biomarkers in lymphoma.

Studies of epigenetic regulation in lymphomas are identifying clinically-useful biomarkers and revealing biological insights into how lymphomas function. Lymphomas exhibit a great degree of epigenetic heterogeneity, which is an indicator of disease aggressiveness and increases the populations of cells that can survive chemotherapy and repopulate the disease.

Cytosine methylation patterns in lymphoma are reversible. The potential remains to inhibit DNA methyltransferases and overcome the negative effects of epigenetic heterogeneity.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center